Logical Therapeutics Inc.
This article was originally published in Start Up
Executive Summary
The gastrointestinal problems linked to NSAIDS are certainly no secret: the ability to mitigate them turned Vioxx into a blockbuster drug, that is, until it was pulled from the market because of cardiovascular problems. Now, Logical Therapeutics in-licensed rights to a pro-drug of naproxen that it thinks will have the GI-safety profile of Vioxx and the cardiovascular safety profile of naproxen.
You may also be interested in...
Logical Therapeutics' Check List: Finish Phase II Studies For Naproxen Pro-Drug, Find A Buyer
Logical hopes Phase II results for its lead anti-inflammatory drug will open the door for a potential buyer.
Logical Therapeutics' Check List: Finish Phase II Studies For Naproxen Pro-Drug, Find A Buyer
Logical hopes Phase II results for its lead anti-inflammatory drug will open the door for a potential buyer.
Start-Up Previews (5/07)
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group: In Inflammation, the Indication's the Thing, features profiles of Anthera Pharmaceuticals, Logical Therapeutics, Opsona Therapeutics and VLST Corp.. Plus these Start-Ups Across Health Care: Biodesy, Magenta Medical and NuLens.